YBX1 and neoplasm: One is to target the GSDME–YBX1–mucin pathway to deprive PDAC cells of their resistance to enzymatic digestion; another is to motivate the pore-forming activity of GSDME to trigger tumour cell pyroptosis and to activate antitumour immune responses.